^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + vibostolimab (MK-7684) (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-3 Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial
Published date:
06/26/2022
Excerpt:
When evaluated by PD-L1 status, ORR was 27% (3/11; 3 PR) in PD-L1-positive and 0% (0/13) in PD-L1-negative tumors. Of 20 patients with PD-L1 CPS data, overall ORR was 15% (3/20; 3 PR); ORR was 33% (3/9; 3 PR) in patients with CPS 1 and 0% (0/11) in patients with CPS < 1....In patients with advanced PD-1/PD-L1 inhibitor-naive GC, vibostolimab+pembrolizumab...Promising antitumor activity was observed at the vibostolimab 200mg dose and in patients with PD-L1-positive tumors...
DOI:
https://doi.org/10.1016/j.annonc.2022.04.081
Trial ID:
